PPubMed13 Apr 2012Cited 63×

Engaging basic scientists in translational research: identifying opportunities, overcoming obstacles

Jennifer A Hobin, Anne M Deschamps, Richard Bockman, Stanley Cohen, Paul Dechow, Charis Eng, William Galey, Mariana Morris, Sharma Prabhakar, Usha Raj, Peter Rubenstein, John A Smith, Patrick Stover, Nancy Sung, William Talman, Richard Galbraith

Abstract

'Paul Dechow' 'Charis Eng' 'William Galey' 'Mariana Morris' 'Sharma Prabhakar' 'Usha Raj' 'Peter Rubenstein' 'John A Smith' 'Patrick Stover' 'Nancy Sung' 'William Talman' 'Richard Galbraith'] This report is based on the Federation of American Societies for Experimental Biology’s symposium, “Engaging basic Scientists in Translational Research: Identifying Opportunities, Overcoming Obstacles,” held in Chevy Chase, MD, March 24-25, 2011. Meeting participants examined the benefits of engaging basic scientists in translational research, the challenges to their participation in translational research, and the roles that research institutions, funding organizations, professional societies, and scientific publishers can play to address these challenges.

§ The Valyu brief

The paper, in five minutes

Read from the full text via Valyu Contents

Engaging basic scientists in translational research yields health benefits but faces cultural, infrastructural, and funding challenges that require coordinated recommendations.

What’s new

i.Identified the benefits of basic scientists’ participation in translational research
ii.Documented the cultural, infrastructural, and funding challenges hindering engagement
iii.Provided recommendations for institutions, societies, publishers, and funders to overcome obstacles

How they did it

The authors organized the FASEB symposium on March 24‑25 2011, pairing basic scientists with senior leaders for panel discussions. They collected survey responses from participants and synthesized observations from case studies and institutional examples. The findings were compiled into this report.

What they found

Nearly three‑quarters of survey respondents began translational work to impact a specific disease; more than half wanted a broader human‑health impact
MDMX is amplified in 65 % of retinoblastoma patients
A heart‑damage‑reducing inhibitor lowered damage by 70 % in animal models
The university’s center brought three new therapies to clinic in 2009, one in 2010, and five in 2011
About 60 % of VA intramural investigators are clinicians

Caveats

✕Cultural and mindset differences between basic and clinical researchers impede collaboration
✕Insufficient infrastructure for protocol development, IRB navigation, and resource sharing
✕Limited training programs and mentorship opportunities for translational research
✕Funding mechanisms often lack expertise to review translational proposals and may be insufficient

§ The Valyu brief

Reading the full paper and taking notes. This takes a few seconds…

§ Ask this paper

Ask a question about this paper

Valyu reads the full text and answers from what the paper actually says.

§ Related work in other archives

Engaging basic scientists in translational research: identifying opportunities, overcoming obstacles

The paper, in five minutes

Ask a question about this paper

Similar papers in all four archives

The paper, in five minutes

Similar papers in all four archives